Edgar Jacoby, Ansgar Schuffenhauer, Maxim Popov, Kamal Azzaoui, Benjamin Havill, Ulrich Schopfer, Caroline Engeloch, Jaroslav Stanek, Pierre Acklin, Pascal Rigollier, Friederike Stoll, Guido Koch, Peter Meier, David Orain, Rudolph Giger, Jurgen Hinrichs, Karine Malagu, Jurg Zimmermann and Hans- Joerg Roth Pages 397 - 411 ( 15 )
The NIBR (Novartis Institutes for BioMedical Research) compound collection enrichment and enhancement project integrates corporate internal combinatorial compound synthesis and external compound acquisition activities in order to build up a comprehensive screening collection for a modern drug discovery organization. The main purpose of the screening collection is to supply the Novartis drug discovery pipeline with hit-to-lead compounds for todays and the futures portfolio of drug discovery programs, and to provide tool compounds for the chemogenomics investigation of novel biological pathways and circuits. As such, it integrates designed focused and diversity-based compound sets from the synthetic and natural paradigms able to cope with druggable and currently deemed undruggable targets and molecular interaction modes. Herein, we will summarize together with new trends published in the literature, scientific challenges faced and key approaches taken at NIBR to match the chemical and biological spaces., Key, Aspects, of, the, Novartis, Compound, Collection, Enhancement, Project, for, the, Compilation, of, a, Comprehensive, Chemogenomics, Drug, Discovery, Screening, Collection
Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.